How Does Microbiome Therapeutics Aid Healthcare?

A microbiome consists of trillions of microorganisms of thousands of varying species. It includes parasites, fungi, bacteria, and viruses. The largest number of microorganisms are found in small and large intestines. The microbiome is considered a supporting organ as it supports the daily smooth operations of the human body.

The microbiome therapeutics industry has garnered $314.4 million revenue, and it is projected to generate $2,036.4 million, advancing at a rate of 23.1% from 2021 to 2030.

Get the sample pages of this report: https://bit.ly/3Xhs1DV

Each individual has their own unique network of microbiota, relying on one’s DNA. For the first time, an individual is exposed to microorganisms as an infant, in the birth canal, and through the breast milk of the mother. One’s microbiome can be altered later relying on environmental exposures and diet. It could bring health benefits, or might cause a great risk for disease.

The microbes in the microbiome could be beneficial and harmful also. Most are symbiotic, and several are pathogenic. Both, symbiotic microbiota and pathogenic microbiota can coexist without causing any problems. A slight disturbance in balance caused by certain diets, infectious illnesses or prolonged use of antibiotics, or others results into dybiosis, and prevention of normal interactions. Thus, body becomes more susceptible to disease.

The growing prevalence of the infectious and gastrointestinal diseases, lead to increasing usage of the microbiome therapeutics to provide the effective treatment. In addition, such treatments are also used for gut-related disorders, including C. diff. Infection (CDI), ulcerative colitis, inflammatory bowel disease.

Furthermore, the surging incidences of the microbial dysbiosis also leads to growing usage of the antibiotic therapy, and surging number of clinical trials for developing specific digestive health-relevant therapies.

The major companies operating in the industry are:

1- Seres Therapeutics Inc.

2- Enterome

3- AOBiome LLC

4- Ferring International Center S.A.

5- Destiny Pharma Plc

6- SANOFI S.A.

7- Taisho Pharmaceutical Holdings Co. Ltd.

Therefore, the rising prevalence of gastrointestinal diseases and gut related disorders lead to increasing demand for microbe therabiotics.